Isavuconazonium Intravenous and Zykadia
Determining the interaction of Isavuconazonium Intravenous and Zykadia and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT). When a single dose of isavuconazonium sulfate (equivalent to 200 mg of isavuconazole) was administered to healthy volunteers following multiple dosing of the potent CYP450 3A4 inhibitor ketoconazole (200 mg twice daily for 24 days), isavuconazole peak plasma concentration (Cmax) increased by 9% and systemic exposure (AUC) increased by 422%. MANAGEMENT: Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours). References "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc, Deerfield, IL.
Professional:CONTRAINDICATED: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of isavuconazole, which is primarily metabolized by CYP450 3A4 and 3A5 and subsequently by uridine diphosphate glucuronosyltransferases (UGT). When a single dose of isavuconazonium sulfate (equivalent to 200 mg of isavuconazole) was administered to healthy volunteers following multiple dosing of the potent CYP450 3A4 inhibitor ketoconazole (200 mg twice daily for 24 days), isavuconazole peak plasma concentration (Cmax) increased by 9% and systemic exposure (AUC) increased by 422%.
MANAGEMENT: Concomitant use of isavuconazonium sulfate with potent CYP450 3A4 inhibitors is considered contraindicated. Ritonavir given at low dosages as a pharmacokinetic booster may be used with caution, but is contraindicated at high dosages (e.g., 400 mg every 12 hours).
- "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc, Deerfield, IL.
Generic Name: isavuconazonium
Brand name: Cresemba
Synonyms: Isavuconazonium, Isavuconazonium Sulfate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Isavuconazonium Intravenous-Zylet
- Isavuconazonium Intravenous-Zylet ophthalmic
- Isavuconazonium Intravenous-Zyloprim
- Isavuconazonium Intravenous-Zymine Liquid
- Isavuconazonium Intravenous-Zymine-D
- Isavuconazonium Intravenous-Zyncof
- Zykadia-Isavuconazonium Sulfate
- Zykadia-Isavuconazonium Sulfate Capsules
- Zykadia-Isavuconazonium Sulfate Injection
- Zykadia-Isentress
- Zykadia-Isentress (Raltegravir Chewable Tablets)
- Zykadia-Isentress (Raltegravir Powder for Oral Suspension)